JCAR017 (also known as lisocabtagene maraleucel)

JCAR017, also called lisocabtagene maraleucel, is a type of CAR T-cell therapy designed to treat certain blood cancers like lymphoma. It involves collecting a patient’s T-cells (a type of immune cell), modifying them in a lab to better recognize and attack cancer cells, and then infusing them back into the patient. This personalized therapy helps the immune system target and destroy cancer cells more effectively. It offers a potent treatment option, especially for patients who haven’t responded to previous therapies, with the goal of achieving remission and improving quality of life.